UOB Kay Hian’s report noted that the HSI and MSCI China Index sagged 4.3% and 5.2%, respectively, in April, wrought by U.S. President Donald Trump’s tariff announcements and concerns over a potential global recession. Amid ongoing external uncertainties, UOB Kay Hian will maintain allocations to domestic policy beneficiaries and defensive sectors. It added BABA-W (09988.HK)  +1.000 (+0.824%)    Short selling $1.34B; Ratio 10.254%   , INNOVENT BIO (01801.HK)  -1.150 (-2.199%)    Short selling $116.95M; Ratio 6.835%   , SHUANGHUAN DRIVELINE (002472.SZ)  +0.420 (+1.224%)   , and TRIP.COM-S (09961.HK)  +9.200 (+1.907%)    Short selling $410.03M; Ratio 25.845%   to its Buy list, while taking profits on CHINA RES LAND (01109.HK)  +0.100 (+0.377%)    Short selling $103.93M; Ratio 16.894%   and JBM HEALTHCARE (02161.HK)  +0.010 (+0.448%)   .

The broker added BABA-W to the Buy list due to: a) successful listings of its business units, b) sustained improvement in cloud’s profitability, and c) strong user growth. INNOVENT BIO was included for: a) strong earnings outlook, b) smooth R&D progress and ongoing business development, and c) new product launches expected to generate revenue. TRIP.COM-S was added given its online travel agency (OTA) platform’s growing penetration in offline and lower-tier city tourism markets, alongside expanded outbound flight capacity.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-05-07 16:25.) (A Shares quote is delayed for at least 15 mins.)

Related NewsCICC Elevates INNOVENT BIO's TP to $66; 1Q25 Rev. in Line